ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Luis Paz-Ares MD PhD: Longer Survival Among Patients with Extensive Stage Small Cell Lung Cancer Treated with Lurbinectedin Maintenance —ASCO 2025"
Episode Synopsis
Audio Journal of Oncology
An interview with:
Luis G Paz-Ares MD PhD, Chair of Medical Oncology, Hospital Universitario 12 de Octubre, Universitario de Madrid
Comment by:
Julie R. Gralow MD FACP FASCO, Chief Medical Officer and Executive Vice President, American Society of Clinical Oncology.
https://www.audiomedica.com/wp-content/2025/06/Luis-Paz-Ares-PRODUCTION-MASTER-.mp3CHICAGO, USA—Patients with extensive stage small cell lung cancer had longer disease-free survival and lived longer when the drug lurbinectedin (a DNA damaging agent) was added to their maintenance therapy after induction using standard immunochemotherapy. At the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO) the Audio Journal of Oncology heard from lead-author of the phase three IMforte study, Luis G Paz-Ares MD PhD from the University Hospital of the 12th of October in Madrid Spain and from Julie R. Gralow MD FACP FASCO, Chief Medical Officer and Executive Vice President of ASCO.
Podcast Script:
SARAH MAXWELL:
Hello and welcome to the Audio Journal of Oncology. I’m Sarah Maxwell. We’re reporting from the 2025 Annual Meeting of the American Society of Clinical Oncology held in Chicago.
There was encouraging news from the phase-three IMforte trial in patients with small cell lung cancer. The addition of a new DNA damaging agent – lurbinectedin – seems to be adding statistically significant and clinically meaningful extensions of progression-free and overall survival.
First Author Luis Paz-Ares, who chairs the Medical Oncology Department at the University of the 12th of October in Madrid, has been telling Peter Goodwin about the study findings:
INTERVIEW: Paz Ares/Goodwin
SARAH MAXWELL:
To get a comment on what Dr. Paz-Ares had to say, Peter attended an ASCO press briefing about the IMforte trial. It was chaired by ASCO’s Chief Medical Officer and Executive Vice President: Julie Gralow, who gave her reactions:
COMMENT: Julie Gralow MD FACP FASCO
Julie Gralow of the American Society of Clinical Oncology, adding her thoughts to what Luis Paz-Ares told us about the IMforte trial results in patients with small-cell lung cancer. And that’s all from this edition of the Audio Journal of Oncology. From me, Sarah Maxwell, goodbye.
ASCO ABSTRACT TITLE
“Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial.”
https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.8006
https://www.audiomedica.com/wp-content/2025/06/Luis-Paz-Ares-PRODUCTION-MASTER-1-1.mp3
An interview with:
Luis G Paz-Ares MD PhD, Chair of Medical Oncology, Hospital Universitario 12 de Octubre, Universitario de Madrid
Comment by:
Julie R. Gralow MD FACP FASCO, Chief Medical Officer and Executive Vice President, American Society of Clinical Oncology.
https://www.audiomedica.com/wp-content/2025/06/Luis-Paz-Ares-PRODUCTION-MASTER-.mp3CHICAGO, USA—Patients with extensive stage small cell lung cancer had longer disease-free survival and lived longer when the drug lurbinectedin (a DNA damaging agent) was added to their maintenance therapy after induction using standard immunochemotherapy. At the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO) the Audio Journal of Oncology heard from lead-author of the phase three IMforte study, Luis G Paz-Ares MD PhD from the University Hospital of the 12th of October in Madrid Spain and from Julie R. Gralow MD FACP FASCO, Chief Medical Officer and Executive Vice President of ASCO.
Podcast Script:
SARAH MAXWELL:
Hello and welcome to the Audio Journal of Oncology. I’m Sarah Maxwell. We’re reporting from the 2025 Annual Meeting of the American Society of Clinical Oncology held in Chicago.
There was encouraging news from the phase-three IMforte trial in patients with small cell lung cancer. The addition of a new DNA damaging agent – lurbinectedin – seems to be adding statistically significant and clinically meaningful extensions of progression-free and overall survival.
First Author Luis Paz-Ares, who chairs the Medical Oncology Department at the University of the 12th of October in Madrid, has been telling Peter Goodwin about the study findings:
INTERVIEW: Paz Ares/Goodwin
SARAH MAXWELL:
To get a comment on what Dr. Paz-Ares had to say, Peter attended an ASCO press briefing about the IMforte trial. It was chaired by ASCO’s Chief Medical Officer and Executive Vice President: Julie Gralow, who gave her reactions:
COMMENT: Julie Gralow MD FACP FASCO
Julie Gralow of the American Society of Clinical Oncology, adding her thoughts to what Luis Paz-Ares told us about the IMforte trial results in patients with small-cell lung cancer. And that’s all from this edition of the Audio Journal of Oncology. From me, Sarah Maxwell, goodbye.
ASCO ABSTRACT TITLE
“Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial.”
https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.8006
https://www.audiomedica.com/wp-content/2025/06/Luis-Paz-Ares-PRODUCTION-MASTER-1-1.mp3
In God we trust